1
|
Gottlieb A, Merola J, Somani N, Konicek B, See K, McKean-Matthews M, Gallo G, Rich P. 293 Ixekizumab demonstrates comprehensive psoriasis clearance in patients with moderate-to-severe psoriasis with scalp, nail, and/or palmoplantar involvement: Uncover-1, -2 trials through 5 years. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
2
|
Ryan C, Guenther L, Foley P, Weisman J, Burge RT, Gallo G, See K, McKean-Matthews M, Bertram CC, Merola JF. Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial. J Eur Acad Dermatol Venereol 2021; 36:e277-e279. [PMID: 34812561 PMCID: PMC9299771 DOI: 10.1111/jdv.17836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Revised: 11/12/2021] [Accepted: 11/18/2021] [Indexed: 11/29/2022]
Affiliation(s)
- C Ryan
- Charles Institute of Dermatology, University College, Dublin, Ireland.,Institute of Dermatologists, Dublin, Ireland
| | - L Guenther
- Guenther Dermatology Research Centre, London, ON, Canada
| | - P Foley
- Skin Health Institute, Melbourne, VIC, Australia
| | - J Weisman
- Medical Dermatology Specialists, Atlanta, GA, USA
| | - R T Burge
- Eli Lilly and Company, Indianapolis, IN, USA.,University of Cincinnati, Cincinnati, OH, USA
| | - G Gallo
- Eli Lilly and Company, Indianapolis, IN, USA
| | - K See
- Eli Lilly and Company, Indianapolis, IN, USA
| | | | - C C Bertram
- Eli Lilly and Company, Indianapolis, IN, USA
| | | |
Collapse
|
3
|
Rosmarin D, Smith S, Shrom D, Burge R, See K, McKean‐Matthews M, Ridenour T, Lin C, Gorelick J. Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non-responders: Subgroup analysis of UNCOVER-3 trial. Skin Health Dis 2021; 1:e43. [PMID: 35663140 PMCID: PMC9060090 DOI: 10.1002/ski2.43] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
| | - S. Smith
- California Dermatology and Clinical Research InstituteEncinitasCaliforniaUSA
| | - D. Shrom
- Eli Lilly and CompanyIndianapolisIndianaUSA
| | - R. Burge
- Eli Lilly and CompanyIndianapolisIndianaUSA
- Division of Pharmaceutical SciencesUniversity of CincinnatiCincinnatiOhioUSA
| | - K. See
- Eli Lilly and CompanyIndianapolisIndianaUSA
| | | | | | - C.‐Y. Lin
- Eli Lilly and CompanyIndianapolisIndianaUSA
| | - J. Gorelick
- California Skin InstituteSan JoseCaliforniaUSA
| |
Collapse
|
4
|
Leonardi C, Warren R, See K, Burge R, Gallo G, McKean-Matthews M, Park S, de la Cruz C, El Sayed M, Strober B. 649 Validation of the Optimal Psoriasis Assessment Tool (OPAT) as a method of assessing psoriasis severity and impact from physician and patient perspectives. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.679] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
5
|
Stirling R, Brand M, Earnest A, Antippa P, Ball D, Bartlett J, Blum R, Briggs L, Caldecott M, Conron M, Jennings B, Langton D, Millar J, Mitchell P, Olesen I, Parente P, Richardson G, See K, Torres J, Underhill C, Wright G, Stenger M, Mcneil J, Zalcberg J. OA05.06 Lessons Learned from the Victorian Lung Cancer Registry: Opportunities for Quality Improvement in Lung Cancer Management and Outcomes. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Huynh L, See K, Tran J, Jaime A, Su H, Ahlering T. Validation of Patient-Reported Outcomes Via Online Questionnaires (PROVOQ) as a quality improvement and urinary continence assessment tool following radical prostatectomy. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32715-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
7
|
Leonardi C, See K, Burge R, Gallo G, McKean-Matthews M, Goldblum O, Wu J. 541 Evaluation of optimal psoriasis assessment tool (OPAT) incorporating both clinical and patient-reported outcomes for treatment of moderate-to-severe plaque psoriasis. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Leonardi C, Mroweitz U, See K, Shrom D, McKean-Matthews M, Gallo G, Nickoloff B, Wu J. 713 The association between disease severity at time of retreatment and probability of recapture in psoriasis patients receiving ixekizumab. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
Leonardi C, Burge R, See K, Shrom D, Guo J, McKean-Matthews M, Amato D, Gallo G, Gooderham M. 540 Rapid response in PASI, sPGA, and BSA measures for patients with moderate-to-severe plaque psoriasis with ixekizumab. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Warren RB, Brnabic A, Saure D, Langley RG, See K, Wu JJ, Schacht A, Mallbris L, Nast A. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. Br J Dermatol 2018; 178:1064-1071. [PMID: 29171861 DOI: 10.1111/bjd.16140] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/14/2017] [Indexed: 12/24/2022]
Abstract
BACKGROUND Head-to-head randomized studies comparing ixekizumab and secukinumab in the treatment of psoriasis are not available. OBJECTIVES To assess efficacy and quality of life using matching-adjusted indirect comparisons for treatment with ixekizumab vs. secukinumab. METHODS Psoriasis Area and Severity Index (PASI) improvement of at least 75%, 90% and 100% and Dermatology Life Quality Index (DLQI) 0/1 response rates for approved dosages of ixekizumab (160 mg at Week 0, then 80 mg every two weeks for the first 12 weeks) and secukinumab (300 mg at Weeks 0, 1, 2, 3 and 4, then 300 mg every 4 weeks) treatment were compared using data from active (etanercept and ustekinumab) and placebo-controlled studies. Comparisons were made using the Bucher (BU) method and two modified versions of the Signorovitch (SG) method (SG total and SG separate). Subsequently, results based on active treatment common comparators were combined using generic inverse-variance meta-analysis. RESULTS In the meta-analysis of studies with active comparators, PASI 90 response rates were 12·7% [95% confidence interval (CI) 5·5-19·8, P = 0·0005], 10·0% (95% CI 2·1-18·0, P = 0·01) and 11·2% (95% CI 3·2-19·1, P = 0·006) higher and PASI 100 response rates were 11·7% (95% CI 5·9-17·5, P < 0·001), 12·7% (95% CI 6·0-19·4, P < 0·001) and 13·1% (95% CI 6·3-19·9, P < 0·001) higher for ixekizumab compared with secukinumab using BU, SG total and SG separate methods. PASI 75 results were comparable when SG methods were used and favoured ixekizumab when the BU method was used. Week 12 DLQI 0/1 response rates did not differ significantly. CONCLUSIONS Ixekizumab had higher PASI 90 and PASI 100 responses at week 12 compared with secukinumab using adjusted indirect comparisons.
Collapse
Affiliation(s)
- R B Warren
- Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, U.K
| | - A Brnabic
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, U.S.A
| | - D Saure
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, U.S.A
| | - R G Langley
- Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Halifax, NS, Canada
| | - K See
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, U.S.A
| | - J J Wu
- Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, U.S.A
| | - A Schacht
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, U.S.A
| | - L Mallbris
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, U.S.A
| | - A Nast
- Division of Evidence-Based Medicine, Department of Dermatology, Venereology and Allergology, Charité Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
11
|
See K, Manser R, Park E, Steinfort D, Piccolo F, Manners D. MA 14.09 Impact of Lung Cancer Perceived Risk, Screening Eligibility and Worry on LDCT Screening Preference - Challenges for Engaging Patients at High Risk. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Steinfort D, Zaw S, King B, Joshi S, Farouque O, Al-Kaisey A, Johnson D, Irving L, Manners D, See K. P2.13-023 Lung Cancer Risk and Eligibility for Lung Cancer Screening in Patients Undergoing Computed Tomography Coronary Angiography. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
13
|
Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol 2017; 31:1004-1013. [PMID: 28190255 PMCID: PMC5485049 DOI: 10.1111/jdv.14163] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Accepted: 01/13/2017] [Indexed: 12/29/2022]
Abstract
Background Continuous treatment is recommended for patients with moderate‐to‐severe psoriasis; however, treatment may need to be interrupted in routine clinical practice. Objective To assess outcomes in patients continuously treated with ixekizumab versus those who interrupted therapy and were subsequently retreated with ixekizumab (IXE). Methods This analysis used data pooled from two phase 3 trials, UNCOVER‐1 and UNCOVER‐2. Patients were randomized to placebo (PBO), IXE every 4 (Q4W) or IXE every 2 weeks (Q2W) for 12 weeks. Patients with a static Physician's Global Assessment (sPGA) 0, 1 at Week 12 were rerandomized to IXEQ4W, IXE every 12 weeks (not presented) or PBO. We examined outcomes in patients who were continuously treated (IXEQ2W/IXEQ4W; IXEQ4W/IXEQ4W) or withdrawn (IXEQ2W/PBO; IXEQ4W/PBO), and in patients who were withdrawn and retreated with IXEQ4W for 24 weeks after disease relapse (sPGA ≥3). Results A total of 1226 treated patients achieved an sPGA 0, 1 at Week 12 and entered the maintenance phase; of these patients, 402 and 416 were rerandomized to PBO and IXEQ4W, respectively. Among patients interrupting treatment, 157 (82.2%) of IXEQ4W/PBO and 176 (83.4%) of IXEQ2W/PBO had an sPGA ≥3 by Week 60; median time to relapse was approximately 20 weeks irrespective of induction dose. At Week 60, continuously treated patients maintained high levels of PASI and sPGA responses (90.0% PASI 75 IXEQ2W/IXEQ4W; 81.9% sPGA 0, 1 IXEQ2W/IXEQ4W, non‐responder imputation). After 24 weeks of retreatment with IXEQ4W (IXEQ2W/PBO/IXEQ4W and IXEQ4W/PBO/IXEQ4W), 87.0% (107 of 123) and 95.1% (97 of 102) (observed), respectively, of patients recaptured PASI 75 and 70.7% (104 of 147) and 82.3% (107 of 130) (observed) recaptured an sPGA 0, 1. Overall, adverse events in continuously treated and retreated patients were comparable. Conclusion High levels of response were sustained with continuous ixekizumab treatment through 60 weeks. Most patients who were withdrawn experienced disease relapse, and most of those patients recaptured response after 24 weeks of retreatment.
Collapse
Affiliation(s)
- A Blauvelt
- Oregon Medical Research Center, Portland, OR, USA
| | - K A Papp
- Probity Medical Research and K. Papp Clinical Research, Waterloo, ON, Canada
| | - H Sofen
- Department of Medicine (Dermatology), David Geffen School of Medicine, Los Angeles, CA, USA
| | - M Augustin
- Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg, Hamburg, Germany
| | - G Yosipovitch
- Department of Dermatology, Miller School of Medicine, University of Miami, Miami, FL, USA
| | - N Katoh
- Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan
| | - U Mrowietz
- Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany
| | - M Ohtsuki
- Department of Dermatology, Jichi Medical University, Shimotsuke, Tochigi, Japan
| | - Y Poulin
- Department of Medicine, Université Laval, Hôpital Hôtel-Dieu de Québec, Quebec, QC, Canada.,Centre de Recherche Dermatologique du Québec Métropolitain, Quebec, QC, Canada
| | - D Shrom
- Eli Lilly and Company, Indianapolis, IN, USA
| | - R Burge
- Eli Lilly and Company, Indianapolis, IN, USA
| | - K See
- Eli Lilly and Company, Indianapolis, IN, USA
| | - L Mallbris
- Eli Lilly and Company, Indianapolis, IN, USA
| | - K B Gordon
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| |
Collapse
|
14
|
Vujic A, Robinson EL, Ito M, Haider S, Ackers-Johnson M, See K, Methner C, Figg N, Brien P, Roderick HL, Skepper J, A Ferguson-Smith, Foo RS. Experimental heart failure modelled by the cardiomyocyte-specific loss of an epigenome modifier, DNMT3B. J Mol Cell Cardiol 2015; 82:174-83. [PMID: 25784084 DOI: 10.1016/j.yjmcc.2015.03.007] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/08/2014] [Revised: 03/06/2015] [Accepted: 03/09/2015] [Indexed: 12/18/2022]
Abstract
Differential DNA methylation exists in the epigenome of end-stage failing human hearts but whether it contributes to disease progression is presently unknown. Here, we report that cardiac specific deletion of Dnmt3b, the predominant DNA methyltransferase in adult mouse hearts, leads to an accelerated progression to severe systolic insufficiency and myocardial thinning without a preceding hypertrophic response. This was accompanied by widespread myocardial interstitial fibrosis and myo-sarcomeric disarray. By targeted candidate gene quantitative RT-PCR, we discovered an over-activity of cryptic splice sites in the sarcomeric gene Myh7, resulting in a transcript with 8 exons missing. Moreover, a region of differential methylation overlies the splice site locus in the hearts of the cardiac-specific conditional knockout (CKO) mice. Although abundant and complex forms of alternative splice variants have been reported in diseased hearts and the contribution of each remains to be understood in further detail, our results demonstrate for the first time that a link may exist between alternative splicing and the cardiac epigenome. In particular, this gives the novel evidence whereby the loss of an epigenome modifier promotes the development and progression of heart disease.
Collapse
Affiliation(s)
- A Vujic
- Division of Cardiovascular Medicine, Addenbrooke's Centre for Clinical Investigation Building, University of Cambridge, Cambridge CB2 0QQ, UK; Cardiovascular Research Institute, Centre for Translational Medicine MD6, National University Health System, 117599 Singapore
| | - E L Robinson
- Division of Cardiovascular Medicine, Addenbrooke's Centre for Clinical Investigation Building, University of Cambridge, Cambridge CB2 0QQ, UK
| | - M Ito
- Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, UK
| | - S Haider
- Centre for Molecular Oncology, Barts Cancer Institute, London EC1M 6BQ, UK
| | - M Ackers-Johnson
- Division of Cardiovascular Medicine, Addenbrooke's Centre for Clinical Investigation Building, University of Cambridge, Cambridge CB2 0QQ, UK; Cardiovascular Research Institute, Centre for Translational Medicine MD6, National University Health System, 117599 Singapore; Genome Institute of Singapore, 60 Biopolis Street, 138672 Singapore
| | - K See
- Genome Institute of Singapore, 60 Biopolis Street, 138672 Singapore
| | - C Methner
- Clinical Pharmacology Unit, Addenbrooke's Centre for Clinical Investigation Building, University of Cambridge, Cambridge CB2 0QQ, UK
| | - N Figg
- Division of Cardiovascular Medicine, Addenbrooke's Centre for Clinical Investigation Building, University of Cambridge, Cambridge CB2 0QQ, UK
| | - P Brien
- Epigenetics ISP, Babraham Institute, Cambridge CB22 3AT, UK
| | - H L Roderick
- Epigenetics ISP, Babraham Institute, Cambridge CB22 3AT, UK
| | - J Skepper
- Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, UK
| | - A Ferguson-Smith
- Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, UK
| | - R S Foo
- Division of Cardiovascular Medicine, Addenbrooke's Centre for Clinical Investigation Building, University of Cambridge, Cambridge CB2 0QQ, UK; Cardiovascular Research Institute, Centre for Translational Medicine MD6, National University Health System, 117599 Singapore; Genome Institute of Singapore, 60 Biopolis Street, 138672 Singapore.
| |
Collapse
|
15
|
Mukhopadhyay A, Leong B, Lua A, Aroos R, Wong J, Koh N, Goh N, See K, Phua J, Kowitlawakul Y. Prospective observational study of handover in a medical ICU. Crit Care 2013. [PMCID: PMC3642925 DOI: 10.1186/cc12462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
16
|
Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009; 20:2095-104. [PMID: 19350340 DOI: 10.1007/s00198-009-0917-y] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2008] [Accepted: 03/04/2009] [Indexed: 12/17/2022]
Abstract
SUMMARY The effects of teriparatide versus alendronate were compared by gender and menopausal status in patients with glucocorticoid-induced osteoporosis. At 18 months, increases in lumbar spine BMD were significantly greater in the teriparatide versus alendronate group in postmenopausal women (7.8% versus 3.7%, p < 0.001), premenopausal women (7.0% versus 0.7%, p < 0.001), and men (7.3% versus 3.7%, p = 0.03). INTRODUCTION In patients with glucocorticoid-induced osteoporosis (GIO), teriparatide significantly increased bone mineral density (BMD) and decreased vertebral fractures compared with alendronate. We examined effects of teriparatide versus alendronate by gender and menopausal status. METHODS This was a multicenter, randomized, double-blind study of teriparatide 20 microg/day versus alendronate 10 mg/day in patients with GIO (277 postmenopausal women, 67 premenopausal women, 83 men). Primary outcome was change in lumbar spine BMD. Secondary outcomes included change in hip BMD, change in bone biomarkers, fracture incidence, and safety. RESULTS At 18 months, mean percent increases from baseline in lumbar spine BMD were significantly greater in the teriparatide versus alendronate group in postmenopausal women (7.8% versus 3.7%, p < 0.001), premenopausal women (7.0% versus 0.7%, p < 0.001), and men (7.3% versus 3.7%, p = 0.03). Radiographic vertebral fractures occurred in one teriparatide (one postmenopausal) and ten alendronate patients (six postmenopausal, four men), and nonvertebral fractures occurred in 12 teriparatide (nine postmenopausal, two premenopausal, one man) and eight alendronate patients (six postmenopausal, two men). The proportion of patients reporting adverse events in teriparatide versus alendronate groups was consistent across subgroups. CONCLUSION Among men and pre- and postmenopausal women with GIO, lumbar spine BMD increased more in patients receiving teriparatide compared with alendronate.
Collapse
Affiliation(s)
- B L Langdahl
- Aarhus University Hospital, Aarhus Sygehus, Tage Hansens Gade 2, 8000 Aarhus, Denmark.
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
See K, Noble RB, Bailer AJ. Computing inclusion probabilities to obtain Horvitz–Thompson estimators for sampling plans excluding neighbouring units. J STAT COMPUT SIM 2007. [DOI: 10.1080/10629360600840308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
See K, Stufken J, Song S, Bailer A. Relative efficienctes of sampling plans for selecting a small number of units from a rectangular region. J STAT COMPUT SIM 2000. [DOI: 10.1080/00949650008812029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
See K, Bailer AJ. Added risk and inverse estimation for count responses in reproductive aquatic toxicology studies. Biometrics 1998; 54:67-73. [PMID: 9544508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
One of the experimental designs used to evaluate the toxicity of certain chemicals in aquatic organisms focuses on reproductive output. Toxic effects are manifested through a reduced level of reproduction in exposed organisms. Historically, evaluating risks in this context has focused on changes in the mean reproduction in a population of organisms. In this paper, we focus on the toxic effects at the level of the individual organism. This new method for count responses involves added risk, the probability of the production of young being suppressed below certain specified levels in individuals exposed to a particular concentration level relative to the probability of that level of suppression in control organisms. This probability serves as the basis of the individual-based risk estimation procedures. In particular, inverse estimation of the concentration associated with a specified added risk and estimates of the added risk associated with a particular concentration are discussed in the context of a negative binomial regression model. Confidence intervals are constructed for both of these quantities using the delta method. These methods are illustrated with a study of an aquatic organism, Ceriodaphnia dubia, exposed to the herbicide nitrofen.
Collapse
Affiliation(s)
- K See
- Department of Mathematics and Statistics, Miami University, Oxford, Ohio 45056, USA
| | | |
Collapse
|
20
|
See K, Bergquist S. Pharmacist as a provider of oncology ambulatory care services. Am J Hosp Pharm 1976; 33:1145-7. [PMID: 998630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The services provided by a pharmacist to ambulatory oncology patients is described. The pharmacist takes drug histories, monitors drug therapy, gives patient discharge consultations and acts in cooperation with local physicians and the medical staff in providing chemotherapy to cancer patients for home administration. The pharmacist also provides inservice education and acts as a consultant to the medical, nursing and pharmacy staffs.
Collapse
|